Newly Published Data Demonstrates Positive Outcomes Resulting from Pathnostics' Advanced Urinary Tract Infection (UTI) Test
IRVINE, Calif., June 20, 2023 /PRNewswire/ -- Pathnostics, a leading precision diagnostic testing and development company, today announced the publication of two new studies demonstrating positive outcomes resulting from its advanced urinary tract infection (UTI) test. The studies show that treatment based on the company's Guidance® UTI test resulted in decreased health care resource utilization and costs compared to standard urine culture (SUC) tests, as well as reduced antibiotic resistance in patients with complicated urinary tract infections.
- In fact, average one-year costs related to UTIs were $501.85 lower for patients receiving treatment based on the Guidance® test than for those based on the traditional culture test.
- In addition, results showed patients diagnosed via the Guidance® test had improved outcomes, including fewer inpatient episodes and lower inpatient costs.
- Separately, data published in the peer-reviewed journal Infection and Drug Resistance suggests that treatment based upon Guidance® UTI testing resulted in reduced antibiotic resistance in symptomatic patients with suspected complicated UTIs.
- "These new findings, combined with ongoing studies, support our mission of increasing access to advanced UTI testing that supports more informed treatment leading to improved outcomes."